Table 6. Prognostic value of NLR and SUVmax.
| Clinical factors | N | mOS (m) | HR | 95% CI | P a | ||
|---|---|---|---|---|---|---|---|
| Risk group | Risk score | <0.001 | |||||
| A | 0 | NLR<2.5 &SUVmax<4.5 | 25 | 11.8 | 1 | reference | |
| B | 1 | NLR<2.5 &SUVmax≥4.5 or 2.5≤NLR<4.5 &SUVmax<4.5 | 43 | 9.8 | 1.536 | 0.896–2.630 | 0.118 |
| C | 2 | 2.5≤NLR<4.5 &SUVmax≥4.5 or NLR≥4.5 &SUVmax<4.5 | 37 | 7.2 | 2.958 | 1.658–5.279 | <0.001 |
| D | 3 | NLR≥4.5 &SUVmax≥4.5 | 13 | 4.6 | 5.336 | 2.484–11.461 | <0.001 |
CI, confidence interval; HR, hazard ratio; mOS, median overall survival; NLR, neutrophil to lymphocyte ratio; SUVmax, maximum standard uptake value.
aP values were calculated using the Multivariate Cox hazard model adjusted with age, gender, ECOG PS, CA19-9, albumin, ALP, bilirubin, ΔNLR, and lymphocyte by forward stepwise selection.